Hikma Pharmaceuticals PLC

Said Darwazah, the chairman and nephew of founder Samih Darwazah, leads investment decisions for the family office. He works alongside other family members and external advisors. The office's strategic direction is guided by the family council (per public record).

The office leverages the Darwazah family's deep relationships in the Middle East pharmaceutical and healthcare ecosystem. Hikma's own M&A and partnership activity provides a pipeline for co-investment opportunities. The office also sources deals via its network of family offices and private equity firms focused on the region.

Yes, it operates as a single family office dedicated to the Darwazah family of Hikma Pharmaceuticals. The office manages the personal wealth of several family members, distinct from the corporate treasury of Hikma PLC. It maintains a lean team with a focus on direct investments.

The office primarily targets healthcare, pharmaceuticals, and life sciences, reflecting the family's core domain expertise. It also has exposure to real estate, infrastructure, and public equities. Investments are concentrated in the UK, Jordan, and MENA markets.

The wealth originates from Samih Darwazah's founding of Hikma Pharmaceuticals in 1978. Hikma is now a multi-billion dollar generic and injectable drug manufacturer listed on the London Stock Exchange. The Darwazah family retains over 40% of the company's shares (per Hikma annual report).

Yes, the family operates the Samih Darwazah Foundation, established by the founder, which focuses on education and healthcare initiatives in Jordan and across the Middle East. The foundation is separate from the family office's investment pool and is funded by Hikma dividends (per public record).